Physician profile
Manisha S Kumar
NPI 1164524088
$1,969.42
in general payments reported to CMS, 2019-2025
13 companies · $760 in 2025
The $760 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $119 · 2021: $113 · 2022: $156 · 2023: $337 · 2024: $155 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,251.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $848.53 | 2019-2025 | Otezla, Evenity, Prolia |
| Abbvie INC. | $159.36 | 2019-2023 | |
| Pfizer INC. | $137.40 | 2019-2025 | |
| Horizon Therapeutics Plc | $133.53 | 2019-2022 | |
| Genentech USA, INC. | $127.59 | 2019-2025 | Actemra |
| Janssen Scientific Affairs, LLC | $118.60 | 2023 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $113.11 | 2022-2024 | Saphnelo |
| Aurinia Pharma U.S., INC. | $95.58 | 2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $94.18 | 2021-2025 | |
| Ucb, INC. | $77.37 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $34.33 | 2021-2024 | Tremfya |
| Sandoz INC. | $15.09 | 2025 | Hyrimoz |
| Lilly USA, LLC | $14.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manisha Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.